The role of SGLT2 inhibitors in managing type 2 diabetes

被引：19

作者：

Tat, Velen ^{[1
,2
]}

Forest, Christopher P. ^{[3
,4
]}

机构：

[1] Arrowhead Reg Med Ctr, Colton, CA 92324 USA

[2] Univ Southern Calif, Keck Sch Med, Primary Care PA Program, Alhambra, CA USA

[3] Calif State Univ Monterey Bay, Hlth Sci & Human Serv, Seaside, CA USA

[4] Master Sci PA Program, Seaside, CA USA

来源：

JAAPA-JOURNAL OF THE AMERICAN ACADEMY OF PHYSICIAN ASSISTANTS | 2018年 / 31卷 / 06期

关键词：

SGLT2; inhibitor; diabetes; canagliflozin; dapagliflozin; empagliflozin; ertugliflozin; major adverse cardiac event; COTRANSPORTER; 2; INHIBITORS;

D O I：

10.1097/01.JAA.0000533660.86287.04

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The sodium glucose cotransporter 2 (SGLT2) inhibitors canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin represent a novel class of medications to manage type 2 diabetes through urinary excretion of glucose. These drugs block glucose reabsorption by the kidneys to increase glucosuria. These drugs provide hemoglobin A1C reduction, promote weight loss, and remain hypoglycemic-neutral when not used in combination with insulin or secretagogues. Canagliflozin and empagliflozin have shown cardiovascular benefit. The potential to reduce the risk of cardiovascular death in patients with type 2 diabetes, along with the benefit of weight reduction, makes these new agents useful tools for the primary care provider.

引用

页码：35 / 40

页数：6

共 21 条

[1] SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study [J].

Abdul-Ghani, Muhammad ;

Del Prato, Stefano ;

Chilton, Robert ;

DeFronzo, Ralph A. .

DIABETES CARE, 2016, 39 (05) :717-725

[2] Diabetes Advocacy: Standards of Medical Care in Diabetes-2018 [J].

不详 .

DIABETES CARE, 2018, 41 :S152-S153

[3]

[Anonymous], 2017, CAN PRESCR INF

[4]

[Anonymous], 2017, DAP PRESCR INF

[5]

[Anonymous], 2017, ERT PRESCR INF

[6]

[Anonymous], 2017, National Diabetes Statistics Report

[7]

[Anonymous], 2017, EMP PRESCR INF

[8] Projection of the year 2050 burden of diabetes in the US adult population: dynamic modeling of incidence, mortality, and prediabetes prevalence [J].

Boyle, James P. ;

Thompson, Theodore J. ;

Gregg, Edward W. ;

Barker, Lawrence E. ;

Williamson, David F. .

POPULATION HEALTH METRICS, 2010, 8

[9] The potential role of sodium glucose co-transporter 2 inhibitors in the early treatment of type 2 diabetes mellitus [J].

Brunton, S. A. .

INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2015, 69 (10) :1071-1087

[10] Achievement of Glycated Hemoglobin Goals in the US Remains Unchanged Through 2014 [J].

Carls, Ginger ;

Huynh, Johnny ;

Tuttle, Edward ;

Yee, John ;

Edelman, Steven V. .

DIABETES THERAPY, 2017, 8 (04) :863-873

← 1 2 3 →